{{Rsnum
|rsid=17110453
|Gene=CYP2C8
|Chromosome=10
|position=96829529
|Orientation=plus
|GMAF=0.1584
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=131
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
}}
{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 82.3 | 16.8 | 0.9
| HCB | 43.1 | 46.0 | 10.9
| JPT | 34.8 | 54.5 | 10.7
| YRI | 99.3 | 0.7 | 0.0
| ASW | 98.2 | 1.8 | 0.0
| CHB | 43.1 | 46.0 | 10.9
| CHD | 50.5 | 43.1 | 6.4
| GIH | 51.5 | 38.6 | 9.9
| LWK | 0.0 | 0.0 | 0.0
| MEX | 77.6 | 20.7 | 1.7
| MKK | 90.4 | 9.6 | 0.0
| TSI | 80.4 | 17.6 | 2.0
| HapMapRevision=28
}}

{{omim
|desc=MYELOMA, MULTIPLE
|id=254500
|rsnum=17110453
}}

{{PMID Auto
|PMID=17048007
|Title=Association of warfarin dose with genes involved in its action and metabolism.
|OA=1
}}

{{PMID Auto
|PMID=18594024
|Title=Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis.
}}

{{PMID Auto
|PMID=19761371
|Title=Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies.
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}